New brain cancer drug shows promise in Mid-Stage trial
NCT ID NCT04250922
Summary
This trial is testing whether adding an experimental drug called LAM561 to standard treatment helps people newly diagnosed with an aggressive brain cancer called glioblastoma. About 144 participants will receive either LAM561 or a placebo pill along with their standard radiation and chemotherapy. The main goal is to see if LAM561 can help control the cancer for longer and help patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cambridge university hospital
Cambridge, United Kingdom
-
Centre Eugène Marquis (CEM)
Rennes, France
-
Freeman Hospital's Northern Centre of Cancer Care
Newcastle, Newcastle Upon Tyne, NE7 7DN, United Kingdom
-
Gustave Roussy University Hospital
Rennes, France
-
Hospital Clinic
Barcelona, Barcelona, Spain
-
Hospital Clínico San Carlos
Madrid, Madrid, Spain
-
Hospital Parc Tauli
Sabadell, Spain
-
Hospital Universitari i Politécnic La Fe.
Valencia, Valencia, 46026, Spain
-
Hospital Universitario 12 De Octubre
Madrid, Spain
-
Hospital Universitario Reina Sofía
Córdoba, Andalusia, Spain
-
Hospital Universitario Virgen del Rocío
Seville, Andalusia, Spain
-
Hospital Vall d'Hebron
Barcelona, Barcelona, Spain
-
Hospital del Mar
Barcelona, Spain
-
Institut Cancerologie de L'Ouest (ICO)
Angers, France
-
Institut universitaire du cancer
Toulouse, France
-
Istituto Nazionale Neurologico Carlo Besta
Milan, Italy
-
Istituto Nazionale Tumori "Regina Elena"
Roma, Italy
-
Istituto Oncologico Veneto IRCCS
Padua, Veneto, 35131, Italy
-
Reaserch Fund of the Hadassah Medical Organization
Jerusalem, Israel
-
The Royal Marsden Hospital
London, United Kingdom
-
University Hospitals Birmingham NHS Foundation Trust - New Queen Elizabeth Hospital
Birmingham, United Kingdom
-
University of Turin
Turin, Italy
Conditions
Explore the condition pages connected to this study.